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Abstract  
Background: Most of Multiple Sclerosis (MS) patients without previous optic neuritis (ON) show 
thinner retinal measurements compared to healthy controls. We aimed to evaluate the role of peripapillary 
retinal nerve fiber layer (pRNFL) thickness or macular volume (MV) in non-ON eyes as a biomarker of 
disability worsening in a cohort of MS patients with at least one non-ON eye available.    
Methods: In this multicenter longitudinal study, we enrolled 879 patients (739 relapsing-remitting and 
141 progressive patients). Disability worsening was assessed using the expanded disability status scale 
(EDSS). pRNFL thickness and MV were assessed by optical coherence tomography (OCT) and 
calculated as the mean value of both non-ON eyes for patients without previous ON or the fellow eye's 
value for those with previous unilateral ON. We estimated the association between pRNFL thickness and 
MV in non-ON eyes, and the risk of disability worsening using proportional hazards models including 
OCT metrics and age, disease duration, disability, presence of previous unilateral ON and use of disease 
modifying therapies as covariates. 
Findings: Disability worsening was noted in 252 out of 879 (29%) patients after a mean follow-up of 
2.32 years of follow-up. MS patients with a pRNFL≤92-93μm in non-ON eyes were associated with a 
58% increased risk of disability worsening as compared to patients with pRNFL>92-93μm, at any time 
after the first year of ascertainment in this cohort [HR=1.58 95% CI (1.13-2.21); p=0.007]. Further, a 
pRNFL ≤87-88μm doubled the risk of disability worsening at any time during the second and third year 
of follow-up [HR=2.06 95%CI (1.36-3.11); p=0.001], and increased the risk by four-fold after 4-5 years 
of follow-up [HR=3.81 95% CI (1.63-8.91) p=0.002]. We did not identify meaningful associations for 
disability worsening with MV. 
Interpretation: Our results provide compelling evidence of the utility of monitoring pRNFL thickness by 
OCT for predicting the likelihood of disability worsening in MS patients over time.  
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Putting research into context 
Evidence before this study 
We searched Pubmed for articles on retinal atrophy by optical coherence tomography and disability 
worsening/progression in multiple sclerosis published before 15 October 2015 using the following terms: 
"optical coherence tomography AND Multiple Sclerosis" and "retinal nerve fiber layer thickness AND 
Multiple Sclerosis". We identified several studies addressing the association between disability in patients 
with multiple sclerosis and retinal nerve fiber layer thickness or/and macular volume assessed by optical 
coherence tomography (OCT). However, most of the data available to date have been collected using 
time-domain OCT (which is less accurate and reproducible as compared to the spectral domain OCT 
devices) in cross-sectional designs. Most of these previous studies were included in a systematic review 
This meta-analysis found inverse correlations (r=-0.3 to r=-0.7) between expanded disability status scale 
(EDSS) and retinal nerve fiber layer thickness in 67% of the included studies. Nevertheless, definitive 
longitudinal evidence linking changes in retinal architecture as a valid and useful surrogate end-point to 
disability worsening in MS is still lacking. 
Added value of this study 
Herein, we report, using multicenter longitudinal cohorts of 879 MS patients that the thickness of the 
peripapillary retinal nerve fiber layer (pRNFL) is a marker of risk of increased disability, as measured by 
the validated expanded disability status scale (EDSS). This multicenter, collaborative initiative to assess 
the value of this novel biomarker to inform about risk of disability worsening in short and medium terms 
in patients with multiple sclerosis provides evidences of the usefulness of OCT imaging for monitoring 
MS course.  
Implications of all the available evidence  
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Our results support the use of pRNFL thickness as a marker of disability worsening in multiple sclerosis. 
Our findings might help neurologist to monitor of the disease in clinical settings and more importantly to 
help drive treatment decisions based on a marker of neuro-axonal damage. Quantification of pRNFL will 
identify patients at high risk of disability worsening, using the cut-offs identified, that will be most 
informative population to be recruited for randomized clinical trials testing neuroprotective or 
regenerative drugs, thereby reducing sample size and associated costs. 
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INTRODUCTION 
Multiple sclerosis (MS) is a disease with an unpredictable course, which makes it very difficult 
to provide accurate prognostic information on an individual patient basis, representing a challenge for 
developing personalized medicine1. Developing an imaging biomarker for MS, in order to predict the 
clinical course and future disability will improve the clinical management, as well as may be useful for 
targeting the most appropriate patients to be enrolled in randomized clinical trials (RCT) testing 
neuroprotective or regenerative drugs2.  
The retina of patients with MS displays inflammatory and neurodegenerative findings3. Optical 
coherence tomography (OCT) is a well-tolerated, accurate and high-resolution imaging modality to 
evaluate retinal integrity. Peripapillary retinal nerve fiber layer (pRNFL) thickness and macular volume 
(MV) have been the most reported OCT measures to evaluate the construct of retinal atrophy. MV is used 
to ascertain retinal ganglion cell integrity, because most of them are located in the macula. Since 2010, 
macular retinal ganglion cell layer thickness is also quantified based on novel segmentation algorithms. 
Studies using spectral-domain OCT have so far revealed that the retina in eyes without previous 
optic neuritis (non-ON eyes) shows thinner pRNFL and retinal ganglion cell layer thickness in most of 
the patients compared to healthy controls, and this was observed in all MS phenotypes including benign 
MS4-6.  All of these OCT parameters have been associated with MS disability7,8 and brain atrophy7,9 and 
for this reason its application offers the promise of being used as an imaging surrogate of the MS disease 
course. 
Nevertheless, up till now, most of the data have been collected using time-domain OCT (which 
is less accurate and reproducible than the new spectral domain devices10) in cross-sectional or short-term 
studies11. A definitive longitudinal evidence linking changes in retinal architecture as a valid and useful 
surrogate end-point of disability worsening in MS is a high research priority12. 
Based on the unmet need of biomarkers for predicting the course of MS, the aim of this study 
was to evaluate if a single assessment of the pRNFL thickness or MV by OCT in non-ON eyes can be 
used as a biomarker of the risk of disability worsening in a large multicenter cohort of MS patients with a 
longitudinal ascertainment of up to 5 years. 
 
METHODS 
Study design 
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The IMSVISUAL (http://www.imsvisual.org) database is composed of longitudinal cohorts 
either already published or being collected as part of ongoing prospective studies. All MS patients gave 
written informed consent and all of the prospective studies whose de-identified data were in the 
IMSVISUAL repository have been approved by their respective Institutional Review Boards. We 
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
Statement for reporting the data of our observational study.   
 
Study population  
In this large, multicenter, longitudinal cohort study, we enrolled patients (age > 16 years old) 
with clinically isolated syndrome (CIS) or MS according to the revised 2010 McDonald Criteria13, 
including relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS) 
subtypes. Patients from the database were only included in the analysis if longitudinal information 
regarding neurological disability from baseline to up to 5 years of follow-up was available 
Retinal atrophy after acute ON is often more pronounced than the retinal thinning observed in 
the absence of ON in MS11,14. For this reason eyes with previous ON were excluded form the analysis. 
Consequently, we only selected patients with at least one non-ON eye available. Previous diagnoses of 
ophthalmological, neurological or drug-related causes of vision loss or retinal damage not attributable to 
MS are exclusion criteria for IMSVISUAL repository entry as described elsewere9,15.  
The IMSVISUAL database included 1,043 out of 1,595 patients with available information on 
longitudinal disability; 879 out of 1,043 patients had OCT data from at least one non-ON eye (Figure 1). 
 
Collection of demographics and clinical data 
We collected a set of clinical variables at baseline, including age at inclusion, sex, disease 
duration, MS subtype, disability measures, previous history of ON, and use of disease modifying 
therapies (DMTs). Neurological disability was evaluated by the expanded disability status scale (EDSS). 
Multiple sclerosis functional composite (MSFC) was available only for a sub-set of participants (n=197), 
and was used as an additional outcome measurement of disability. The presence of prior ON was assessed 
in the subjects’ medical record, as previously described16.   The same neurologist and ophthalmologist in 
each centre examined the patients during the follow-up in the study. 
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Definition of the end-point: disability worsening 
Disability worsening (confirmed accumulation of disability) was defined following recent 
criteria as a documented increase in neurologic disability (at least one-point increase in the EDSS score, 
or half-point increase for patients with a baseline score ≥5.5, confirmed in a second visit 3 to 6 months 
apart) as a result of relapses or progressive disease12. EDSS assessment was always performed in the 
absence of acute relapses. MSFC worsening was defined as having maintained worsening ≥ 20% by any 
of three components17. Disability worsening (yes/no) was estimated once for each patient at any time of 
follow-up and with either EDSS or MSFC.  
 
Definition of the OCT measurements in non-ON eyes  
pRNFL thickness and MV (6 mm ring area) were evaluated once at baseline visit by using 
spectral-domain OCT, either Spectralis® (Heidelberg Engineering, Germany) or CirrusTM (Carl Zeiss, 
Dublin, US). The pRNFL thickness and MV were calculated as the mean values of both non-ON eyes, 
except for patients with a previous history of unilateral ON, of whom only the fellow non-ON eye's 
values entered the analyses.  
In order to identify the cases of subclinical ON, we used a previously described approach based 
on the interocular asymmetry in the pRNFL thickness and MV by OCT15 (see supplementary results for 
details). Only eight patients (6 imaged with Spectralis® and 2 with Cirrus™) with both eyes tagged as 
non-ON eye met this criterion for pRNFL thickness and 10 patients (7 imaged with Spectralis® and 3 
with Cirrus™), for MV. For these patients, we included only the eye with the highest pRNFL thickness 
and MV value. 
 
Statistical analysis 
We described baseline features of the study population and the distribution of events (disability 
worsening) by key demographic and clinical characteristics using absolute and relative frequencies for 
categorical variables and medians, P25, P75 and interquartile ranges for quantitative variables for 
describing baseline features of the study population and P20, P40, P60, P80 for describing distribution of 
events.  
Considering the different periods of follow-up for patients in the study, we fitted proportional 
hazards models (PHMs) to evaluate pRNFL thickness and MV in non-ON eyes as markers of the risk of 
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disability worsening. First, we evaluated these OCT measures quantitatively and then, we used median 
and tertiles to categorize pRNFL thickness and MV in two and three equally sized groups as an approach 
to merge data from both devices and to assess the non-linear relationship between retinal integrity and 
disability worsening. We defined pRNFL as the primary end-point of the study because it has better 
signal to noise ration than MV (see discussion for biological basis). We ran PHMs including only OCT 
measures in the models to provide unadjusted HRs for pRNFL thickness and MV.  We estimated the 
Kaplan-Meier plots of cumulative incidence of disability worsening during the follow-up in the two 
groups (split by median) and three groups (split by tertiles) for the primary end-point for the study in the 
total population and for MS subgroups18.  
We compared baseline features between the patients who developed disability worsening and the 
patients who remained stable at the end of the follow-up. We performed these bivariate analyses by using 
Fisher's exact test for categorical data and Mann-Whitney-U test for quantitative variables. We ran PHMs 
to assess the univariate impact of each one of these features in the risk of disability worsening. We ran 
PHMs including all these covariates to estimate the adjusted HR for OCT measures for the study 
population and for the subgroups. 
A key assumption in these models is proportional hazards. We used time dependent covariates, 
including interaction terms with time, to assess proportionality for each covariate included in the model, 
namely age, previous ON, disease duration, EDSS at baseline, use of DMTs and OCT metrics in PHMs. 
We evaluated linear interaction [covariate*Time], logarithmic interactions [covariate*LN (Time) and 
covariate*LG10 (Time)] and also we evaluated the effect of these covariates during the first year of 
follow-up [covariate*Time≤1.00], from first to third year [covariate *Time>1.00 and ≤3.00] and finally 
from third to fifth year [covariate *Time>3.00 and ≤5.00]. Baseline EDSS (models including total study 
population), disease duration and presence of previous ON (models including progressive MS (PMS) 
subgroup) showed non-proportionality for the analyses of pRNFL thickness. Median MV also displayed 
non-proportionality. Thus, we extended the PHM by adding the interaction between the non-proportional 
covariate and the time of observation also as covariate. A patient who displayed disability worsening 
within a given follow-up period was excluded for the analyses of subsequent follow-up periods because 
we only included patients who were free of the event of interest to evaluate the risk of disability 
worsening in the next follow-up period. A patient who did not present the event at a given follow-up 
period was included for the analyses of the next follow-up period only if we had available information 
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about his/her disability status during the next follow-up period; otherwise, he/she was censured. We used 
the likelihood ratio test and Harrell´s C statistics to evaluate the goodness-of-fit of PHMs. The accuracy 
and significance of the coefficients estimated by the proportional hazards methods would become un-
trustworthy when the number of events per variable (EVP) is lower than ten19,20. Thus, we considered this 
cut-off point as a reference and we only ran PHMs with EVP≥10. Two-tailed p-values <0.05 were 
considered statistically significant. Analyses were performed with the Statistical Package IBM-SPSS 
(SPSS Inc, Chicago, IL, USA) software version 20.0 for Mac. Harrell´s C statistic estimations were 
performed with SAS version 9.4. 
 
Role of funding source 
 The funding agencies had no role in the design nor conduct of the study; collection, 
management, analysis, and interpretation of the data; or preparation, review, or approval of the 
manuscript. The raw IMSVISUAL dataset is available at the IMSVISUAL website 
(http://www.imsvisual.org) for registered researchers upon request. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
Baseline characteristics of study population 
The study population included 879 MS patients (Figure 1, Table 1). The cohort included mainly 
a mildly to moderately disabled population, with a median EDSS of 2.0. Information about therapies was 
available for 557 participants. Only 533 patients out of 879 had MV values available. 
 
Patient’s characteristics categorized by disability worsening 
We identified 252 out of 879 (29%) patients who displayed disability worsening after the follow-
up. The study follow-up period ranged from 1 to 5 years (mean 2.32 years and median 2.00 years). Table 
2 showed the comparison of baseline characteristics between patients with disability worsening and those 
with stable MS after follow-up. Patients who developed disability worsening were older, suffered more 
frequently PMS and had longer disease duration at baseline. Moreover, the prevalence of unilateral ON 
prior to study enrollment was higher for patients who remained stable during follow-up. Patients who 
showed disability worsening less frequently received DMTs. Table S1 displayed the frequency of events 
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by key demographic and clinical characteristics. We also ran univariate proportional hazards models to 
assess the impact of these baseline features in disability worsening (Table S2). These results showed that 
age, disease duration, baseline disability and the presence of PMS phenotype were directly associated 
with the risk of disability worsening, whereas receiving DMTs and the presence of unilateral ON prior to 
study enrollment were inversely related with the risk of disability worsening during the follow-up.  
 
Baseline pRNFL thickness in non-ON eyes predicts risk of disability worsening 
Unadjusted analyses 
We ran separate PHMs for Spectralis® and Cirrus™ as due to differences between the 
segmentation algorithms, pRNFL thickness quantification is directly not comparable between the two 
devices21 (Spectralis® n=726, Cirrus™ n=162 and 9 patients had studies with both devices). The 
unadjusted hazard ratios (HR) in favor of disability worsening among patients with greater baseline 
pRNFL thickness was HR=0.98 [95%CI (0.97-0.99); p<0.001] for Spectralis® and HR=0.99 [95% CI 
(0.97-1.01); p=0.210] for Cirrus™. These results suggested that higher pRNFL thickness (lower retina 
atrophy) was associated with lower likelihood of disability worsening.   
Previous studies suggested non-linear relationship between retinal atrophy and clinical outcomes 
based in the presence of thresholds for predicting visual disability14,22. Thus, we used median and tertiles 
to categorize pRNFL thickness in two and three equally sized groups and also this approach allowed us to 
pool data from both devices. Patients who had pRNFL thickness ≤92μm at baseline (median) had a 51% 
greater risk of disability worsening [HR=1.51 95%CI (1.17-1.93); p=0.001] compared to patients with 
thicker pRNFL thickness. Next, we compared the risk associated to being allocated in the lower tertile 
[pRNFL≤87μm] and intermediate tertile [pRNFL=87-98μm] versus being included into the higher tertile 
[pRNFL>97-98μm]. We found that patients in the lower tertile at baseline demonstrated increased risk of 
disability worsening [HR=1.65 95% (1.23-2.21); p=0.001] compared to those in the higher tertile, while 
there were no differences between patients of middle and higher tertile (Figure 2).  
 
Adjusted analyses 
We ran PHM including age, previous ON, disease duration, EDSS to evaluate the role of pRNFL 
thickness as a predictor of disability worsening. 
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The adjusted HR for pRNFL thicknesses were HR=0.98 [95%CI (0.97-0.99); p=0.006] for Spectralis® 
and HR=0.98 [95% CI (0.96-1.00); p=0.102] for Cirrus™. When we included also use of DMTs as a 
covariate, the risk of disability worsening associated to pRNFL thinning increased slightly (HR=0.97 
[95% CI (0.95-0.99); p=0.001] for Spectralis® device. The Cirrus™ PHM is not shown because the 
number of EVP including DMTs as covariate was lower than 10 (EVP=9.57). 
 Patients who had a pRNFL≤ 92C-93Sμm showed a 58% increase in the risk of disability 
worsening [HR=1.58; 95%CI (1.13-2.21); p=0.007] when compared to patients with a thicker pRNFL. 
Again, we found that patients in the lower pRNFL thickness tertile displayed increased risk of disability 
worsening [HR=1.75 95% CI (1.19-2.59); p=0.005] compared to those in the higher tertile. There were no 
differences between patients in the intermediate vs. higher tertiles. Thus, we merged the intermediate and 
higher tertiles, and thereby estimated the risk associated to pRNFL thickness in the lower tertile, as 
compared to this new aggregate category. Patients who displayed pRNFL≤87C-88Sμm doubled the risk of 
worsening in the following years compared to patients with greater pRNFL [HR=1.96 95%CI (1.39-
2.76); p<0.001]. All these PHMs were statistically significant (Table 3). 
 Regarding MV, we only found increased risk of disability worsening at any time after the first 
year follow-up until the fourth [HR: 2.02 95%CI (1.03-3.93); p=0.040] for those patients with 
MV≤8.73mm3 (see supplementary results and Table S3).  
 
Disability worsening prediction by pRNFL depends on follow-up time 
The association of the risk of disability worsening with baseline pRNFL for the first year was 
non-significant. Considering than sample size and effects were similar for year 2 and 3 as well as for 
years 4 and 5, we merged these time points. Therefore, as exploratory analyses, we provided estimations 
from baseline to first year; from first to third year and from third to fifth year. Patients with pRNFL 
≤87C/88Sμm doubled the risk of disability worsening [HR=2.06 95% CI (1.36-3.11); p=0.001] at any time 
after the first year and until third year of follow-up. This risk almost increased four-fold [HR=3.81 95% 
CI (1.63-8.91); p=0.002] after the third year and until the fifth year of follow-up (Table 3). 
 
Subgroup analyses: risk of disability worsening in CIS, RRMS and PMS 
There were 74 patients in the CIS subgroup (Cirrus™ n=4 and Spectralis® n=70). We evaluated 
the association between disability worsening and pRNFL thickness in non-ON eyes only in the group 
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with data from Spectralis® (because the small sample size of Cirrus prevented further analysis). We did 
not find associations between pRNFL thickness and risk of disability worsening in the CIS subgroup 
(supplementary figure S3). 
 There were 664 RRMS patients of whom 171 patients (25.7%) presented disability worsening 
during the follow-up. RRMS patients with pRNFL thickness ≤92C/93Sμm at baseline and specially those 
with pRNFL thickness ≤88μm displayed increased risk of disability worsening during follow-up 
(supplementary figure S4). We estimated adjusted HR for pRNFL thickness in non-ON eyes and risk of 
disability worsening in the group of 426 RRMS for whom we had information about use of DMTs 
(supplementary Table S4.1). RRMS Patients with pRNFL≤88μm in non-ON eyes (lower tertile) 
displayed a 90% increase in the risk of disability worsening [HR=1.90; 95%CI (1.27-2.83); p=0.002] 
compared to patients with a thicker pRNFL than these cut-offs in PHMs including the following 
covariates: age, disease duration, previous ON, baseline EDSS, use of DMTs and pRNFL thickness. 
RRMS patients with pRNFL≤88μm had twice the risk [HR=2.17 95% CI (1.34-3.51); p=0.002] of 
disability worsening at any time after the first year and until the third year, and the risk was multiplied by 
almost three [HR=2.77 95% CI (1.12-6.85); p=0.028] thereafter until the end of follow-up in our study 
(supplementary results and Table S4.2). 
 There were 83 SPMS and 58 PPMS patients. Considering the sample size, we merged both 
phenotypes in a group of PMS of 141 patients (Spectralis® n=123, Cirrus™ n=19, and 1 patient had data 
from both OCT). && out of 141 PMS patients (46.8%) had disability worsening during the follow-up 
(Spectralis®: 60 out of 122 patients (48.7%) and Cirrus™: 6 out of 19 patients (31.5%)). Considering the 
small sample size of patients imaged with Cirrus™, we estimated the association between disability 
worsening and RNFL thickness in non-ON eyes only in PMS patients with data only from Spectralis®. 
We did not find statistically significant differences in the baseline features between PMS with disability 
worsening and those who remained stable (Table S5). PMS patients with pRNFL≤79Sμm at baseline had 
increased risk of disability worsening during the follow-up [HR=1.82 95% CI (1.06-3.11): p=0.030] 
compared to those with pRNFL thicker than this cut-off in a PHM including age, disease duration and 
previous ON as covariates. DMTs have not showed relevant benefit to counteract risk of disability 
worsening in MS patients with progressive phenotype. Therefore, we did not consider this variable in our 
PHMs for PMS patients. We did not have enough EPV to evaluate risk of disability worsening in the 
different periods of follow-up in the PMS subgroup (supplementary results). 
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Sensitivity analyses 
 Finally, we performed sensitivity analysis using an increase ≥1.5 point in the EDSS score as 
criteria for disability worsening for patients with baseline EDSS=0 and another definition of subclinical 
ON based in the interocular asymmetry of RNFL thickness >20%16, founding similar results 
(supplementary Table S6 and Table S7). pRNFL thickness in non-ON eyes may be reduced in patients 
with previous history of ON due to retrograde axonal degeneration of optic nerve fibers since both nerves 
are connected by the chiasm. We evaluated the association between pRNFL thickness and risk of 
disability worsening separately for patients with and without previous unilateral ON. Patients in the lower 
tertile for both groups displayed an increased risk of disability worsening during the follow-up although 
the risk seems to be higher for patients with previous ON (supplementary Table S8). 
 
Power calculation for key findings  
 The key result of this study is that MS patients with pRNFL thickness in non-ON eyes ≤87-
88μm had twice the risk of disability worsening [HR=1.96 95%CI (1.39-2.76); p<0.001] during the 
follow-up. We calculated that the statistical power for this result was 82% under the following 
assumptions: (1) event rates of 25.08% in the group of MS patients with pRNFL thickness >87-88μm and 
35.69% in the group of MS patients with pRNFL thickness ≤87-88μm in a 5-year follow-up period; (2) 
sample size for the group of MS patients with pRNFL thickness >87-88μm equal to 366 and sample size 
for the group of MS patients with pRNFL thickness ≤87-88μm equal to 191 [ratio 2]; (3) an alpha error of 
0.05 and (2) two-tailed test for survival analyses.  
 
DISCUSSION 
In this multicenter longitudinal study we have demonstrated that pRNFL thickness measured by 
OCT, can be used as a marker of worsening of neurological disability over a time horizon of between one 
and five years of follow-up. The key result of this study is that MS patients with pRNFL thickness in non-
ON eyes ≤87-88μm had twice the risk of disability worsening during the follow-up. This risk was 
independent of other factors known to be associated with disability worsening including age, disease 
duration, baseline level of disability (EDSS) and use of DMTs. These results constitute the first step to 
validate the use of OCT as an imaging marker for monitoring MS. 
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 The retina of patients with MS displays neurodegenerative changes such as axonal loss, neuronal 
soma shrinking3. Whether such continuously ongoing or relapsing damage is attributable to retrograde 
axonal degeneration due to subclinical ON or microscopic optic nerve inflammation8, trans-synaptic 
degeneration, primary retina neurodegeneration or systemic effects of inflammation remains unclear15,23.  
Our findings, that patients with a given level of axonal damage, as revealed by pRNFL thickness, are 
more likely to become disabled supports the concepts of a threshold in CNS damage; after which, further 
damage translates to a greater clinical disability. The mechanisms underlying disability worsening in MS 
are not well known but must likely involve acute damage during relapses or chronic CNS inflammation 
(e.g. microglia activation) as well as degenerative processes (neuro-axonal degeneration, transynaptic 
degeneration, myelin loss)24,25. Consequently, as shown in our study, monitoring pRNFL thickness in the 
retina is useful to monitor risk of disability worsening in MS. 
 In this study, we did not evaluate pRNFL thinning over the follow-up and for this reason we 
cannot contribute to whether RNFL thickness decrease overtime. Serbecic N et al have found found that 
pRNFL measurements in MS patient were unchanged compared to baseline6. By contrast, Ratchford JN et 
al found that the rate of ganglion cell plus inner plexiform layers thinning in MS was faster for patients 
with active disease in a cohort of MS patients followed over a two year period8. These studies suggested 
that pRNFL changes might be too subtle to be detected with current OCT systems for short follow-up 
periods and might require longer observation periods. Some authors recommended an observation period 
of at least two years for MS patients without ON11. However, the dynamics of retinal thinning in MS is 
not well established so far so it is not clear how many OCT investigations per year are appropriate to 
evaluate pRNFL thinning and monitor MS course.  
 Brain volume loss by MRI is probably the most commonly used measure of neurodegeneration 
in MS26. However, monitoring neurodegeneration and disability worsening by MRI has methodological 
and biological limitations. In contrast, OCT is technically easier, accessible in many ophthalmologic 
centers and provides an immediate bedside-like outcome such as pRNFL thickness, amenable to be used 
in an outpatient clinic setting as an objective measure of risk of progression supporting the therapeutic 
decision-making process16,27. Spectral-domain OCT with predefined scans protocols has shown very good 
reliability of repeated measures. Finally, pRNFL thickness is a specific measure of axonal loss not 
affected directly by inflammation  (except during acute ON) and less affected by astrogliosis compared to 
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MRI brain volume loss. Therefore, we propose OCT as an imaging marker for MS that would 
complement MRI evaluation.  
The lack of biological specificity of neuronal layer thinning in the retina might explain the lack 
of consistent association of MV with disability worsening in our study. The retina of patients also show 
different changes such as axonal loss, neuronal soma shrinking, synaptic loss, microglia activation and 
astrocyte proliferation3. The ganglion cell complex thinning has been associated with disability7,8 and 
brain atrophy9. Macular inner nuclear layer thinning or thickening has been reported in MS28,29. Also, 
during acute ON, outer retinal layers have consistently been observed to show an increase in 
thickness14,30, may be due to presence of cytotoxic edema30. Thus, MV thickness changes may be much 
more complex and difficult to interpret with several mechanisms being involved in the final disposition of 
its measured magnitude. Future studies applying retinal segmentation may be able to more specifically 
parse layers with glial activation. 
 A striking finding of our study is the effect of the use of MS drugs in the risk of disability 
worsening defined by pRNFL. DMTs reduce the frequency of relapses and new inflammatory MRI 
lesions. As a consequence, it may reduce acute axonal transection. Although, it is unclear if these 
treatments may prevent disability worsening due to diffuse damage, untreated relapsing MS patients 
displayed an independent increased risk of disability worsening according to our results. 
 Our study has several strengths, including the large sample size with statistical power of 82% for 
the main findings, clinical follow-up of up to 5 years and the validation with data from multicenter source 
as well as for different MS phenotypes. However, the study has also some limitations as well. For 
example, our results cannot be applied to MS patients who have experienced bilateral ON. The sample 
size and therefore, the number of events in the progressive MS subgroup was small and these results in 
progressive MS would need further evaluation in studies with larger sample sizes. Also, our study has not 
included patients with pediatric MS and for this reason additional studies will be required for this 
population. This study has not used a central OCT reading centre to evaluate the quality of the OCT data, 
but we included patients from groups with extensive expertise on high-quality OCT research. The 
IMSVISUAL repository did not include MRI data, so we could not evaluate the role of pRNFL thickness 
in comparison to brain atrophy by MRI for predicting disability worsening. The analysis was based on 
eyes without previous ON. In order to identify subclinical ON, we used two previously described 
approaches based on the interocular asymmetry in the pRNFL thickness and MV by OCT15,16. However, 
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IMSVISUAL database did not include neurophysiological data that would be useful to improve the 
identification of subclinical ON. 
  Our results support pRNFL thickness measures as a biomarker of disability worsening in MS 
that may help drive treatment decisions in clinical settings. Additionally, our results would be useful for 
RCTs. RCT needs to enroll patients that are at high risk of presenting the event of interest. Patients may 
fulfill inclusion criteria but some may have low risk of disability worsening (main event). Their inclusion 
may decrease power of a RCT testing a neuroprotective drug because it may not capture the efficacy of 
the drug because lack of events. Patients at high risk of developing disability worsening constitute the 
most informative population for these RCT because they maximize the effect size. Thus, quantification of 
pRNFL thickness by optical coherence tomography in non-ON eyes of MS patients and the proposed cut-
offs will help to identify the most appropriate patients to be enrolled in a RCT; thus reducing the number 
of non-informative patients and the associated costs. Future multicenter prospective studies may solve 
some of these limitations and provide definitive validation of these findings. 
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Ines González has nothing to disclose 
Olivier Outteryck reports grant for research from Novartis; grants and personal fees from Biogen-Idec, 
funding for travel from Biogen-Idec, Genzyme-Sanofi, Merck-Serono, Novartis and Teva Pharmaceutical 
Industries, outside the submitted work. He is a researcher in OCTIMS study. 
Ann-Kristin Mueller has nothing to disclose 
Phillip Albrecht has received speaker honoraria, consulting fees and travel support by Biogen, Novartis, 
TEVA, IPSEN, Merz, Esai, GSK and research grants by Biogen, Merz and Novartis. He is a researcher in 
PASSOS and ARPEGIO aimed to validate OCT as biomarker of MS and sponsored by Novartis and 
TEVA respectively. 
Wesley Chan has nothing to disclose 
Sebastian C Lukas has received speaker fees from Genzyme, Biogen and Heidelberg Engineering and 
has participated in the OCTIMS and the PASSOS studies (sponsored by Novartis). 
Lisanne J. Balk received research support from the Stichting MS Research The Netherlands. He is a 
researcher in OCTIMS study. 
Clare Fraser has nothing to disclose. 
Jette L Frederiksen has served on scientific advisory boards for and received funding of travel for these 
activities and honoraria from Biogen Idec, Merck Serono, Sanofi-Aventis, Genzyme, Teva, Novartis and 
Takeda and has received speaker honoraria from Biogen Idec and Merck Serono. 
Jennifer Resto has nothing to disclose 
Christian Cordano has nothing to disclose 
IMSVISUAL consortium 19 
Irati Zubizarreta has no conflict of interest 
Bernardo Sanchez-Dalmau is a researcher in OCTIMS study. 
Albert Saiz has received compensation for consulting services and speaking from Bayer-Schering, 
Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis. He is a 
researcher in OCTIMS study. 
Robert Bermel has served as a consultant for Biogen, Novartis, Genzyme, and Genentech. 
Alexander Klistorner has nothing to disclose 
Axel Petzold: received consulting fees form Novartis. He received research support from the Stichting 
MS Research The Netherlands. He is a researcher in OCTIMS study and performs QC reading for the 
PASSOS study from Novartis. 
Sven Schippling has received research grants from Biogen, Bayer Healthcare and Genzyme, and 
consulting/speaking fees from Bayer Healthcare, Biogen, Merck Serono, Novartis, TEVA and 
Genzyme/Sanofi. He sits on the Steering Committees of the OCTiMS, BENEFIT, REFINE and EMPIRE 
studies and has participated in the OCTIMS and PASSOS studies (both studies sponsored by Novartis).  
Fiona Costello has nothing to disclose 
Orhan Aktas has received research support from the German Research Council (DFG), the German 
Ministry of Education and Research (BMBF-EDEN), Bayer, Biogen Idec, Merck Serono, Novartis, and 
Teva and serves on an advisory board for MedImmune. He is a researcher in PASSOS and ARPEGIO 
aimed to validate OCT as biomarker of MS and sponsored by Novartis and TEVA respectively. He is an 
academic editor for PLOS ONE. 
Patrick Vermersch has received honoraria and consulting fees from Biogen, Genzyme-Sanofi, Bayer, 
Novartis, Teva, Merck-Serono, GSK and Almirall. Research supports from Biogen, Bayer, Novartis and 
Merck-Serono. He is co-chairman of the scientific advisory board of the OCTIMS study. 
Celia Oreja-Guevara has received honoraria and consulting fees from Biogen, Genzyme-Sanofi, Bayer, 
Novartis, Teva and  Merck-Serono. She is investigator of the observational study OCTIMS. 
Giancarlo Comi has received personal compensation and research funding from Novartis, Teva, Sanofi, 
Genzyme, Merck Serono, Biogen, Bayer, Serono Symposia International Foundation, Roche, Almirall, 
Chugai, Receptos.  
Letizia Leocani has received personal compensation and research funding from Abbvie, Novartis, 
Biogen, Genzyme, Merck Serono, and Almirall 
IMSVISUAL consortium 20 
Elena Garcia-Martin has nothing to disclose 
Friedemann Paul Funding: Deutsche Forschungsgemeinschaft (DFG Exc 257), Bundesministerium für 
Bildung und Forschung (Competence Network Multiple Sclerosis, N2 ADVISIMS), Guthy Jackson 
Charitable Foundation, EU FP7 program (combims.eu), research grants and personal compensation for 
activities with Alexion, Bayer, Chugai, Novartis, Merck, Teva, Sanofi, Genzyme, Biogen, MedImmune. 
Serves as academic editor for PLoS ONE and as associate editor for N2. He is a researcher in OCTIMS 
study and his research group serves as reading center fort he PASSOS study sponsored by Novartis. FP 
serve as a principal investigator for a German OCT study sponsored by Biogen. 
Eva Havrdova has received clinical trials advisory board membership and speaker´s honoraria from 
Biogen, Merck Serono, Novartis, Sanofi Genzyme, Alkermes, Actelion and Teva. He is a researcher in 
OCTIMS study. 
Teresa Frohman has received speaker and consulting fees from Novartis, Genzyme and Acorda.  
Elliot Frohman has received speaker and consulting fees from Novartis, Genzyme, Acorda and TEVA.  
Laura Balcer has received consulting fees from Biogen and Genzyme and has received research funding 
from Biogen.  
Ari Green has received personal fees from Inception Sciences and Mylan Pharmaceuticals and 
grants/awards from Novartis. He also reported serving on end point adjudication committees for Biogen 
and MedImmune. He serves on trial steering committees for Novartis and the scientific advisory board for 
Bionure. He is a researcher in OCTIMS study. 
Peter A Calabresi has received consulting fees from Vertex, Abbvie, and Merck and has received 
research funding from Biogen, Novartis and MedImmune. He is co-chairman of the scientific advisory 
board of OCTIMS study. 
Pablo Villoslada has received consultancy fees from Heidelberg Engineering regarding the clinical 
applications of OCT. He serves as academic editor of Current Treatment Options in Neurology, 
Neurology & Therapy, Multiple Sclerosis & Demyelinating Disorders, PloSONE and MS in focus. He is 
founder and hold stocks in Bionure Inc and Spire Bioventures Inc. He has received consultancy fees from 
Roche, Novartis, Health Engineering and stock options from Mint-Labs. He has received unrestricted 
grants from Genzyme, Roche and Novartis. He is a researcher in OCTIMS study. 
 
References  
IMSVISUAL consortium 21 
1. Gourraud PA, Henry RG, Cree BA, et al. Precision medicine in chronic 
disease management: The multiple sclerosis BioScreen. Ann Neurol 2014; 76(5): 
633-42. 
2. Villoslada P. Biomarkers for multiple sclerosis. Drug News Perspect 2010; 
23(9): 585-95. 
3. Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R. Ocular pathology in 
multiple sclerosis: retinal atrophy and inflammation irrespective of disease 
duration. Brain 2010; 133(6): 1591-601. 
4. Oberwahrenbrock T, Schippling S, Ringelstein M, et al. Retinal damage in 
multiple sclerosis disease subtypes measured by high-resolution optical coherence 
tomography. Mult Scler Int 2012; 2012: 530305. 
5. Huang-Link YM, Fredrikson M, Link H. Benign Multiple Sclerosis is 
Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell 
Layers in Non-Optic-Neuritis Eyes. Journal of clinical neurology 2015; 11(3): 241-7. 
6. Serbecic N, Aboul-Enein F, Beutelspacher SC, et al. High resolution spectral 
domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first 
follow up study over two years. PLoS One 2011; 6(5): e19843. 
7. Abalo-Lojo JM, Limeres CC, Gomez MA, et al. Retinal nerve fiber layer 
thickness, brain atrophy, and disability in multiple sclerosis patients. J 
Neuroophthalmol 2014; 34(1): 23-8. 
8. Ratchford JN, Saidha S, Sotirchos ES, et al. Active MS is associated with 
accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 
80(1): 47-54. 
9. Saidha S, Al-Louzi O, Ratchford JN, et al. Optical coherence tomography 
reflects brain atrophy in MS: A four year study. Ann Neurol 2015; 78(5): 801-13. 
IMSVISUAL consortium 22 
10. Bock M, Brandt AU, Dorr J, et al. Time domain and spectral domain optical 
coherence tomography in multiple sclerosis: a comparative cross-sectional study. 
Mult Scler 2010; 16(7): 893-6. 
11. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in 
multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 
9(9): 921-32. 
12. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of 
multiple sclerosis: The 2013 revisions. . Neurology 2014; 83(3): 278–86. 
13. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple 
sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-
302. 
14. Gabilondo I, Martinez-Lapiscina EH, Fraga-Pumar E, et al. Dynamics of 
retinal injury after acute optic neuritis. Ann Neurol 2015; 77(3): 517-28. 
15. Gabilondo I, Martinez-Lapiscina EH, Martinez-Heras E, et al. Trans-synaptic 
axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol 2014; 
75(1): 98-107. 
16. Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic 
neuritis: a review and proposed protocol. Nat Rev Neurol 2014; 10(8): 447-58. 
17. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with 
the Multiple Sclerosis Functional Composite. Mult Scler 2009; 15(8): 984-97. 
18. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes 
in clinical trials: good practice and pitfalls. Lancet 2002; 359(9318): 1686-9. 
19. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per 
independent variable in proportional hazards analysis. I. Background, goals, and 
general strategy. J clin epidemiol 1995; 48(12): 1495-501. 
IMSVISUAL consortium 23 
20. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per 
independent variable in proportional hazards regression analysis. II. Accuracy and 
precision of regression estimates. J clin epidemiol 1995; 48(12): 1503-10. 
21. Warner CV, Syc SB, Stankiewicz AM, et al. The impact of utilizing different 
optical coherence tomography devices for clinical purposes and in multiple 
sclerosis trials. PLoS One 2011; 6(8): e22947. 
22. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic 
neuritis with optical coherence tomography. Ann Neurol 2006; 59(6): 963-9. 
23. Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal pathology in multiple 
sclerosis as detected by optical coherence tomography. Brain 2011; 134(Pt 2): 
518-33. 
24. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, 
inflammation, and neurodegeneration. Neuron 2006; 52(1): 61-76. 
25. Tallantyre EC, Bo L, Al-Rawashdeh O, et al. Clinico-pathological evidence 
that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 
2010; 16(4): 406-11. 
26. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume 
measures in multiple sclerosis. CNS drugs 2014; 28(2): 147-56. 
27. Galetta SL, Villoslada P, Levin N, et al. Acute optic neuritis: Unmet clinical 
needs and model for new therapies. Neurol neuroimmunol neuroinflamm 2015; 
2(4): e135. 
28. Albrecht P, Ringelstein M, Muller AK, et al. Degeneration of retinal layers in 
multiple sclerosis subtypes quantified by optical coherence tomography. Mult Scler 
2012; 18(10): 1422-9. 
IMSVISUAL consortium 24 
29. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, 
thickness of the inner nuclear layer of the retina, and disease characteristics in 
multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11(11): 963-72. 
30. Al-Louzi OA, Bhargava P, Newsome SD, et al. Outer retinal changes following 
acute optic neuritis. Mult Scler 2015. 
 
IMSVISUAL consortium 25 
Table 1: Baseline demographics and clinical characteristics 
 Study population 
(N=879) 
Sex, female n (%) 584 (66) 
Age (years) 40.6 [32.5-48.7; 16.2] 
Disease duration (years) 6.5 [2.7-13.4; 10.7] 
Multiple sclerosis type   
CIS, n (%) 74 (8) 
  RRMS, n (%) 664 (76) 
SPMS, n (%) 83 (9) 
PPMS, n (%) 58 (7) 
Optic neuritis status   
Previous ON, n (%)  281 (32) 
No previous ON, n (%) 598 (68) 
Treatment (n: 557)  
None, n (%) 150 (17) 
Interferon B 1b sc, n (%) 61 (7) 
Interferon B 1a sc, n (%) 81 (9) 
Interferon B 1a im, n (%) 98 (11) 
  Glatiramer Acetate, n (%) 81 (9) 
Fingolimod, n (%)  14 (2)  
Natalizumab, n (%) 45 (5) 
Others1, n (%) 27 (3) 
Expanded disability status scale (EDSS) 2 [1.5-3.5; 2] 
Multiple sclerosis functional composite (MSFC)  
PASAT (0-60) (n: 197) 49 [36-55; 19] 
Non-Dominant hand (seconds) (n: 195) 21.2 [19.0-23.6; 4.6] 
Dominant hand (seconds) (n: 195) 19.9 [17.9-23.8; 5.9] 
Timed 25-Foot Walk (seconds) (n: 191) 4.6 [3.9-5.7; 1.8] 
Peripapillary retinal nerve fiber layer (RNFL) thickness  
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(µm) 
Spectralis® (n: 726) 92.1 [84.0-99.7; 15.7] 
Cirrus™ (n: 162) 91.6 [84.5-100.4; 15.9] 
Macular volume (mm3)   
Spectralis® (n: 418) 8.5 [8.2-8.8; 0.6] 
Cirrus™ (n: 124) 10.0 [9.8-10.4; 0.6] 
 
Data represents median [P25-P75; interquartile range] unless otherwise indicated.  
1Cyclophosphamide (n=5), Mitoxantrone (n=10), Azathioprine (n=5), Diazoxide (n=2), Flupirtine (n=1) 
and unknown therapy but reported the patient as under therapy (n=4).  
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Table 2 Comparison of baseline characteristics between patients with disability worsening and 
those with stable MS in the study population 
 
Stable 
(n: 627) 
Disability Worsening 
(n: 252) 
P value 
Sex, female n (%) 420 (67) 164 (65) 0.636 
Age (years) 39.6 [31.9 -47.9; 16.0] 43.3 [33.6-50.2; 16.6] 0.001 
Disease duration (years) 6.0  [2.3-12.8; 10.5] 7.37 [3.3-15.0; 11.7] 0.008 
Baseline EDSS 2.0 [1.5-3; 1.5] 2.5 [1.5-4; 2.5] 0.002 
Progressive MS n (%) 75 (12) 66 (26) <0.001 
DMTs, treated n (%) (n: 557) 299 (75) 108 (68) 0.091 
Previous ON status, (yes) 223 (36) 58 (23) <0.001 
EDSS: expanded disability status scale; MS: multiple sclerosis; DMTs: disease modifying therapies; ON: 
optic neuritis. 
Data represents median [P25-P75; interquartile range] unless otherwise indicated.  
Fisher's exact test for categorical data and U-Mann Whitney for quantitative variables  
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Table 3. Proportional hazards models for baseline pRNFL thickness in non-ON eyes as predictor of 
disability worsening in MS. 
Proportional hazards models1 n /N HR (95% IC) P value 
C of Harrell 
(95% IC) 
pRNFLS (µm) 187/726 0.98 (0.97-0.99) 0.006 0.56 
(0.43-0.68) 
pRNFLC (µm) 67/162 0.98 (0.96-1.00) 0.102 --- 
pRNFL (µm) ≤ 92 vs. >92 252/879 1.39 (1.07-1.81) 0.014 
0.57 
(0.41-0.72) 
Follow-up ≤1 year 46/879 1.02 (0.56-1.83) 0.959 
0.58 
(0.42-0.73) 
Follow-up >1 and ≤3 years 163/708 1.44 (1.04-1.93) 0.026 
Follow-up >3 and ≤5 years 43/171 1.70 (0.92-3.14) 0.090 
pRNFL (µm) 87-97S/98C vs. >97S/98C 
252/ 879 
0.97 (0.70-1.34) 0.839 
0.58 
(0.42-0.73) pRNFL (µm) ≤ 87 vs. >97S/98C 1.49 (1.08-2.04) 0.015 
pRNFL (µm) ≤ 87 vs. >87 252/879 1.51 (1.16-1.98) 0.003 
0.57 
(0.41-0.72) 
Follow-up ≤1 year 46/879 0.76 (0.40-1.42) 0.387 
0.57 
(0.41-0.73) 
Follow-up >1 and ≤3 years 163/708 1.65 (1.19-2.28) 0.003 
Follow-up >3 and ≤5 years 43/171 2.28 (1.22-4.25) 0.010 
Proportional hazards models2 n /N HR (95% IC) P value 
C of Harrell 
(95% IC) 
pRNFLS (µm) 94/408 0.97 (0.95-0.99) 0.001 
0.55 
(0.39-0.70) 
pRNFLC (µm)3 ------ ------- ------ ------ 
pRNFL (µm) ≤ 92C/93S vs. >92C/93S 159/557 1.58 (1.13-2.21) 0.007 
0.57 
(0.41-0.72) 
Follow-up ≤1 year 31/557 1.36 (0.66-2.81) 0.405 
0.58 
(0.42-0.73) 
Follow-up >1 and ≤3 years 99/422 1.59 (1.06-2.40) 0.025 
Follow-up >3 and ≤5 years 29/104 1.85 (0.83-4.14) 0.134 
pRNFL (µm) 87C/88S-98 vs. >98 
159/557 
0.78 (0.51-1.20) 0.265 0.58 
(0.42-0.73) pRNFL (µm) ≤87C/88S vs. >98 1.75 (1.19-2.59) 0.005 
pRNFL (µm) ≤87C/88S vs. >87C/88S 159/557 1.96 (1.39-2.76) <0.001 0.57 
(0.41-0.72) 
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n represents the number of events; N is the number of patients at risk entering in the analyses. There were 
9 patients with data from both devices. Thus, the sum of n and N from Spectralis® OCT and C Cirrus™ 
OCT were 254 and 888, respectively instead of 252 and 879 for PHMs1 and 161 and 566 instead of 159 
and 557 for PHMs2  
S Spectralis® OCT; C Cirrus™ OCT; pRNFL: peripapillary retinal nerve fiber layer. 1Results represent 
hazard ratios (HR) and 95% confidence intervals (CI) from proportional hazards models including the 
following variables: age (years), disease duration (years), unilateral optic neuritis (yes/no), baseline 
EDSS, Time (linear)*EDSS and pRNFL thickness. pRNFLS median thickness: 92μm; pRNFLS 
thicknesses: lower tertile: <87μm; intermediate tertile: 87-97 μm and higher tertile > 97μm. pRNFLC 
median thickness: 92μm; pRNFLC thicknesses: lower tertile: <87μm; intermediate tertile: 87-98μm and 
higher tertile > 98μm. 
2Results represent hazard ratios (HR) and 95% confidence intervals (CI) from proportional hazards 
models including the following variables: age (years), disease duration (years), unilateral optic neuritis 
(yes/no), baseline EDSS, Time (linear)*EDSS, use of DMTs (yes/no) and pRNFL thickness. pRNFLS 
median thickness: 93μm. pRNFLS thicknesses: lower tertile: <88μm; intermediate tertile: 88-98μm and 
higher tertile > 98μm. pRNFLC median thickness: 92μm; pRNFLC thicknesses: lower tertile: <87 μm; 
intermediate tertile: 87-98μm and higher tertile > 98μm. 
3 This model was not presented because the number of events per variable was lower than ten 
(EVP=9.57). 
All proportional hazard models were statistically significant with the exception of the PHM including 
only data from Cirrus™ OCT. Therefore; Harrell C´s statistics was not estimated. All proportional hazard 
models were also fitted in a stepwise fashion including all covariates in a first model [age, disease 
duration, unilateral optic neuritis, baseline EDSS and use of DMTs if applicable] and pRNFL thickness in 
a second model. The likelihood ratio test showed the addition of pRNFL thickness improved the models. 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up ≤1 year 31/557 1.06 (0.51-2.23) 0.873 
0.57 
(0.41-0.73) 
Follow-up >1 and ≤3 years 99/422 2.06 (1.36-3.11) 0.001 
Follow-up >3 and ≤5 years 29/104 3.81 (1.63-8.91) 0.002 
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Figure 1. Flow chart of participants through the IMSVISUAL repository and this study. A) displays 
the assessment of the inclusion/exclusion criteria to be enrolled in the study; B) flow chart of participants 
through the study in the different proportional hazard models for the total population and subgroups 
analyses.  
Figure 2. Kaplan-Meier plots of cumulative incidence of disability worsening in the complete MS 
population. A) cumulative percentage of patients with disability worsening during the follow-up in the 
two groups split by median of pRNFL thickness in non-ON eyes; B) cumulative percentage of patients 
with disability worsening during the follow-up in the three groups split by the tertiles of pRNFL thickness 
in non-ON eyes. Number at risk: number of patients at risk just before the selected time-points, namely 
baseline, zero, one, two, three, four and five years of follow-up. HR: hazard ratio; CI: confidence interval; 
RNFL: retinal nerve fiber layer.  
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Figure 1 
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